Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility

Simply Wall St.02-14

AdvertisementWhy Ascentage Pharma Group International (SEHK:6855) Is Drawing Investor Attention Ascentage Pharma Group International (SEHK:6855) has come onto investor radars after recent share price ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611692112?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-14 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611692112","market":"nz","top_or_hot":-1,"title":"Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Ascentage Pharma Group International (SEHK:6855) Is Drawing Investor Attention Ascentage Pharma Group International (SEHK:6855) has come onto investor radars after recent share price ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-14 16:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Ascentage Pharma Group International (SEHK:6855) Is Drawing Investor Attention Ascentage Pharma Group International (SEHK:6855) has come onto investor radars after recent share price ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu","article_id":"2611692112","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611692112","pubTimestamp":1771057713,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Ascentage Pharma Group International (SEHK:6855) Is Drawing Investor Attention\nAscentage Pharma Group International (SEHK:6855) has come onto investor radars after recent share price moves, with a 1 day return of 2.4% and a 7 day gain of 1.3%.\nThese short term shifts contrast with a month decline of 12.8% and a past 3 months drop of 29.7%. This has prompted investors to reassess how the current price of HK$47.5 lines up with the company’s fundamentals.\nSee our latest analysis for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","06855":"亚盛医药-B"},"translate_title":"在近期股价波动后评估亚盛医药集团国际（联交所：6855）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":0.9},"content_text":"AdvertisementWhy Ascentage Pharma Group International (SEHK:6855) Is Drawing Investor Attention Ascentage Pharma Group International (SEHK:6855) has come onto investor radars after recent share price moves, with a 1 day return of 2.4% and a 7 day gain of 1.3%. These short term shifts contrast with a month decline of 12.8% and a past 3 months drop of 29.7%. This has prompted investors to reassess how the current price of HK$47.5 lines up with the company’s fundamentals. See our latest analysis for Ascentage Pharma Group International. That recent rebound in the share price sits against a weaker short term trend, with the year to date share price return of negative 6.7% contrasting with a 1 year total shareholder return of 34.2%. This suggests sentiment has improved over a longer horizon even as near term momentum has faded. If this kind of price volatility has your attention, it can help to broaden your watchlist with other opportunities. Take a look at our screener of 107 healthcare AI stocks as a starting point for finding more ideas in related areas. With Ascentage Pharma still loss making on HK$390.6m of revenue, recent share price swings raise a key question for you: is the current HK$47.5 level an undervalued entry point, or is the market already pricing in future growth? Most Popular Narrative: 21% Undervalued At a last close of HK$47.5 against a most-followed fair value estimate of HK$60.10, the prevailing narrative sees meaningful upside baked into its model.  The assumed bearish price target for Ascentage Pharma Group International is HK$51.97, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Ascentage Pharma Group International's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.  Read the complete narrative. Curious what has to happen for that fair value to hold up? The narrative leans on rapid revenue build, a sharp margin shift, and a rich future earnings multiple. The full story connects those moving parts into one valuation playbook. Result: Fair Value of HK$60.10 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, key risks remain, including pressure on drug pricing in China and any setback in late stage trials that could challenge the growth story underpinning this valuation. Find out about the key risks to this Ascentage Pharma Group International narrative. Another View: Rich P/S Multiple Sends a Different Signal While the DCF work points to Ascentage Pharma trading 83.8% below an assessed fair value of HK$293.53, the current P/S ratio of 39.6x paints a very different picture. It sits well above the Hong Kong Biotechs industry at 13.7x, the peer average at 12.5x, and even the fair ratio of 13.8x. This suggests meaningful valuation risk if expectations reset. Which signal do you put more weight on right now? See what the numbers say about this price — find out in our valuation breakdown. SEHK:6855 P/S Ratio as at Feb 2026 Build Your Own Ascentage Pharma Group International Narrative If you see the numbers differently, or prefer to stress test the assumptions yourself, you can create your own view in minutes: Do it your way A great starting point for your Ascentage Pharma Group International research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Ready for more investment ideas? If Ascentage Pharma has sparked your curiosity, do not stop here. Your next strong idea could be sitting in plain sight, waiting in our screeners.  Target potential mispricings by scanning for opportunities in our 231 high quality undervalued stocks and see which businesses currently trade below their assessed worth. Prioritise resilience by checking companies in the solid balance sheet and fundamentals stocks screener (372 results) where strong finances help underpin the investment case. Get ahead of the crowd by reviewing our screener containing 551 high quality undiscovered gems and spot quality names that many investors may still be overlooking.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611692112","isCrawlerRequest":true}